Trial Profile
A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs Zastumotide (Primary) ; AS15; Interleukin-2
- Indications Malignant melanoma
- Focus Therapeutic Use
- 26 Nov 2018 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 20 Apr 2016 Results (n=16) presented at the 107th Annual Meeting of the American Association for Cancer Research